Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma

Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS)

(2020) Susanna C. Concilio et al.   PLoS One

Armed oncolytic viruses: A kick-start for anti-tumor immunity

(2018) J.F. de Graaf et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Drug resistance in multiple myeloma

(2018) Pawel Robak et al.   CANCER TREATMENT REVIEWS

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

(2018) Stefania Oliva et al.   Frontiers in Immunology

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

(2017) A Dispenzieri et al.   LEUKEMIA

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

(2017) A Miller et al.   Blood Cancer Journal

Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

(2017) Tiphaine Delaunay et al.   OncoImmunology

Dendritic Cell Therapies for Hematologic Malignancies

(2017) Matthew Weinstock et al.   Molecular Therapy-Methods & Clinical Development

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study

(2015) H Suen et al.   LEUKEMIA

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Human Tumor Antigens and Cancer Immunotherapy

(2015) Nathalie Vigneron   Biomed Research International

Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

(2014) E. Galanis et al.   CANCER RESEARCH

Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy

(2014) Stephen J. Russell et al.   MAYO CLINIC PROCEEDINGS

Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients

(2013) Willemijn Hobo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs

(2013) Massimo Martino et al.   Clinical Lymphoma Myeloma & Leukemia

Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma

(2013) Toshihiro Miyamoto et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

G-Protein-Coupled Receptor Kinase-5 Mediates Inflammation but Does Not Regulate Cellular Infiltration or Bacterial Load in a Polymicrobial Sepsis Model in Mice

(2013) Nandakumar Packiriswamy et al.   Journal of Innate Immunity

Oncolytic Viruses for Induction of Anti-Tumor Immunity

(2012) Alex W. Tong et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter for Squamous Cell Cancer of the Head and Neck Radiovirotherapy

(2011) Hongtao Li et al.   HUMAN GENE THERAPY

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma

(2009) D. Atanackovic et al.   CLINICAL CANCER RESEARCH

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

(2008) C L White et al.   GENE THERAPY